Market Overview

Stocks Hitting 52-Week Lows



  • Esperion Therapeutics Inc (NASDAQ: ESPR) shares fell 37.87 percent to touch a new 52-week low of $10.05 after failing to reach an agreement with the FDA regarding a definitive approval path for its ETC-1002, a cholesterol-lowering pill. JP Morgan downgraded Esperion Therapeutics from Overweight to Neutral and lowered the price target from $50.00 to $15.00, while Credit Suisse also downgraded the stock from Neutral to Underperform and lowered the price target from $23.00 to $10.00.
  • Lipocine Inc (NASDAQ: LPCN) shares touched a new 52-week low of $2.98 following announcement of a Complete Response Letter from the FDA. The response letter noted deficiencies in dosing algorithm on label.
  • AEGON N.V. (ADR) (NYSE: AEG) shares touched a new 52-week low of $3.912. Barclays downgraded Aegon from Equal-weight to Underweight.
  • Galena Biopharma Inc (NASDAQ: GALE) shares fell 84.06 percent to reach a new 52-week low of $0.324 after the company revealed it discontinued NeuVax™ (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical study. The company added that on June 27, the IDMC recommended that the PRESENT trial be stopped due to futility.

Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets


Related Articles (AEG + ESPR)

View Comments and Join the Discussion!

Nike's North American Concerns Are Getting Priced In

S&P 500 Index Futures Trading Higher